Encephalitis is a rare, but serious complication from vaccination against smallpox using replication competent strains of vaccinia virus. In this report we describe mutants of vaccinia virus, containing N-terminal deletions of the vaccinia virus interferon resistance gene, E3L, that are attenuated for neuropathogenesis in a mouse model system. These recombinant viruses replicated to high titers in the nasal mucosa after intra-nasal infection of C57BL/6 mice but failed to spread to the lungs or brain. These viruses demonstrated reduced pathogenicity after intracranial infection as well, indicating a decrease in neurovirulence. Intra-nasal inoculation or inoculation by scarification with a low dose of recombinant virus containing a deletion of the entire N-terminal domain of E3L protected against challenge with a high dose of wild-type vaccinia virus, suggesting that this replication competent, but attenuated strain of vaccinia virus may have promise as an improved vaccine for protecting against smallpox, and as a vector for inducing mucosal immunity to heterologous pathogenic organisms. D
Introduction
Vaccinia virus (VV) is a powerful immunogen, with a single dose often providing long-term protection against smallpox (Fenner et al., 1988) . However, nearly 1 in 1000 vaccinated individuals report a complication associated with vaccination using replication competent strains of VV (Fenner et al., 1988) . Amongst the most serious complications is post-vaccination encephalitis, which is most common in vaccinated infants (approximately 1 in 20,000 children immunized with VV under the age of 1 year are diagnosed with encephalitis). This complication has a 30-50% case fatality rate and responds poorly to treatment with antivaccinia Ig.
The WR strain is a mouse-adapted, virulent strain of VV. Intra-cerebral infection of susceptible mice with as little as 10 2 pfu of VV-WR is lethal. Intra-nasal infection of C57BL/ 6 mice with this virus leads to replication in the nasal mucosa and spread to the brain (Brandt and Jacobs, 2001) . Since in the intra-nasal model virus spreads from the periphery to the brain, this model may be an appropriate predictor of neurological complications associated with vaccination. In fact, there appears to be a correlation between neurovirulence of a strain of VV in the mouse model and reactogenicity in humans (Fenner et al., 1988) .
With the goal of defining the mechanisms by which poxviruses evade host defenses we have been studying the VV E3L gene. The E3L gene, which codes for two C-terminal co-linear proteins, p20 and p25, is required for interferon-resistance of VV (Jacobs and Langland, 1996) , and for inhibition of IRF3 activation, a key inducer of IFN gene expression (Smith et al., 2001; Xiang et al., 2002) . The carboxy-terminal domain of E3L encodes a conserved motif that functions to bind double-stranded RNA (dsRNA). This dsRNA-binding domain has been studied in detail and is required for inhibition of the cellular dsRNA-dependent antiviral enzymes, PKR and 2V5V oligo-adenylate synthetase (Chang and Jacobs, 1993; Rivas et al., 1998; Watson et al., 1991) . The importance of the amino terminus of E3L until recently has been elusive. It is not required for IFN resistance or host range of VV in cells in culture ; however, we have recently identified the amino terminus as critical for pathogenesis in a mouse model (Brandt and Jacobs, 2001) .
The N-terminal domain of E3L shows sequence similarity with a group of Z-DNA-binding proteins, ADAR-1 and Dlm (Kim et al., 2003) . In fact, the N-terminus of E3L can bind Z-DNA , and the related domains from ADAR-1 and Dlm can partially complement deletion of the N-terminal domain of E3L (Kim et al., 2003) . Among virus containing mutations in the N-terminal domain of E3L or of an ADAR-1/E3L chimera, pathogenesis correlated with affinity for Z-DNA (Kim et al., 2003) .
VV (strain WR) expressing an amino terminal deletion of 83 amino acids of E3L (VV-E3LD83N) is attenuated in a mouse model by at least 1000-fold compared to wildtype VV when administered via the intra-nasal route (Brandt and Jacobs, 2001 ). These results led us to investigate the specific role that the amino terminus may be playing during a virus infection in mice. In this manuscript we demonstrate that recombinant viruses containing N-terminal deletions in E3L replicate efficiently in the nasal mucosa but fail to spread from the nasal cavity to the lungs or the brain. These virus recombinants exhibit decreased virulence even when injected directly into the brain, likely due to poor replication in neuronal tissue. Intra-nasal infection or infection by scarification with one of these replication competent VV recombinants fully protected against challenge with wild-type VV.
Results

Vaccinia viruses containing amino terminal deletions of the E3L gene are attenuated in a mouse model
The N-terminus of the E3L gene is required for pathogenicity in C57BL/6 or Balb/c mice (Brandt and Jacobs, 2001 ; and data not shown). Intra-nasal infection with as little as 10 4 pfu of wild-type VV killed 50% of infected mice. In contrast, mice infected with VVE3LD83N showed no mortality up to a dose of 10 6 pfu. The intra-nasal LD 50 for VVE3LD83N calculated from three independent experiments was 2 Â 10 7 pfu; greater than 1000 times higher than wild-type VV (1 Â 10 4 pfu).
In order to determine whether the entire N-terminal domain is required for pathogenesis we tested viruses containing nested deletions in the N-terminus of E3L for virulence by intra-nasal infection in the mouse model. E3LD37N synthesizes only the smaller of the two proteins encoded by E3L, p20. E3LD54N is missing approximately half of the conserved N-terminal Z-DNA-binding domain, while E3LD83N is missing the entire N-terminal Z-DNAbinding domain (Kim et al., 2003) . VVE3LD37N had an LD 50 of approximately 5 Â 10 5 pfu after intra-nasal infection (Fig. 1, open triangles) , nearly 50-fold higher than wild-type VV (Fig. 1, open squares) . These results demonstrate that expression of the full-length E3L encoded protein (p25) is necessary to confer full pathogenesis to VV in the mouse model. VVE3LD54N was completely apathogenic after intra-nasal infection with doses as high as 10 7 pfu (Fig. 1 , open circles, and data not shown). The greater reduction in pathogenicity of VVE3LD54N relative to VVE3LD83N is likely due to instability of E3LD54N protein (data not shown). Because of the instability of E3LD54N protein this virus was not further characterized.
Amino terminal mutations decrease neuroinvasiveness of vaccinia virus
The WR strain of VV used in these studies is neurotropic and neurovirulent (Williamson et al., 1990) . After intranasal infection of C57BL/6 mice with the WR strain of VV, the virus replicates to high titer in the nose, and then spreads Fig. 1 . Dose-response mortality curves for intra-nasal infections with virus recombinants containing N-terminal deletions of the E3L gene. Groups of at least six C57BL/6 mice were infected intra-nasally with increasing doses of the indicated viruses as described (see Materials and methods). Animals were monitored for 2 weeks for morbidity, weight loss, and mortality (% survival is shown).
to the lungs and the brain where it also replicates to high titers (Brandt and Jacobs, 2001 ). Prior to euthanasia, animals displayed neurological symptoms, including tremors, seizures, and hyperactivity followed by lethargy. In order to determine at which stage of the disease process N-terminal deletion mutants are attenuated, animals were infected intra-nasally with 10 5 pfu of either wild-type VV or VVE3LD83N. Tissue was isolated from infected animals at 2, 4, and 6 days post-infection and assayed for the amount of virus present. Fig. 2A shows results for wild-type VV. Virus in the nasal cavity was detectable at 2 days postinfection and peaked at 4 days post-infection with a titer greater than 10 8 pfu/gm tissue. Virus spread to the lungs and brain by 4 days post-infection. Results for VVE3LD83N are shown in Fig. 2B . Virus was also detected in the nasal cavities of animals infected with VVE3LD83N by 2 days post-infection. Levels of VVE3LD83N increased through 6 days post-infection to a maximal titer indistinguishable from the peak titer in the nasal cavities of animals infected with wild-type VV. Despite robust replication in nasal mucosa, VVE3LD83N was not detected in the lungs or brain of infected animals. Similar results were obtained for VVE3LD54N and for sub-lethal doses of VVE3LD37N (data not shown).
Amino terminal mutations decrease neurovirulence of vaccinia virus
Since VV recombinants containing N-terminal deletions in the E3L gene did not disseminate from the nose to the brain as in a wild-type infection, it was important to assess neurovirulence directly. Mice were infected intra-cranially with increasing doses of wild-type VV, VVE3LD37N, or VVE3LD83N and monitored for mortality. The results revealed the same order of neurovirulence for these viruses as after intra-nasal infection (wtVV N VVE3LD37N N VVE3LD83N) (Fig. 3A) . The LD 50 for VVE3LD83N after intra-cranial inoculation was approximately 1000-fold higher than the LD 50 for wild-type VV (1 Â 10 5 pfu vs. 1 Â 10 2 pfu, respectively). These results indicated that the full-length N-terminus is required not only for spread from the nasal cavity, but for pathogenesis after direct inoculation in the brain as well.
In order to determine if the decrease in neurovirulence was due to an inability of virus to replicate in neuronal tissue, mice were inoculated intra-cranially with approximately 1 Â 10 6 pfu of wild-type VV or VVE3LD83N. Brains were harvested 3 days post-infection and assayed for infectious virus on RK13 cell monolayers (Fig. 3B ). Wild-type VV achieved titers greater than 10 9 pfu/gm of tissue, whereas VVE3LD83N appeared not to replicate well in the brain, yielding titers of less than 10 5 pfu/gm of tissue (Fig. 3B ). We have also monitored virus replication and spread with strains of VV expressing lacZ from an intergenic locus. Similar to virus not expressing a transgene, VVE3LD83N-lacZ is 1000-fold less pathogenic than wtVV-lacZ (data not shown). For wtVV-lacZ, virus spread from the site of infection in the left hemisphere, with intense h-gal staining throughout the choroid plexus of the lateral ventricles of the brain (Fig. 4A) . On the other hand, there was very little hgal staining in brains of animals infected with VVE3LD83N-lacZ, and the staining was limited to the site of infection (Fig. 4B) . Taken together, these results indicate that this mutant is defective in neurovirulence, likely due to its inability to replicate to high titers in tissue of neuronal origin, possibly in addition to a defect in spread from the nasal mucosa.
The amino terminus of VV E3L is not required to elicit a protective immune response
One of the primary complications to use of VV as a vaccine is encephalitis (Fenner et al., 1988) . The phenotype of VVE3LD83N, replication to high titers in nasal mucosa Fig. 2 . Dissemination of virus after intra-nasal inoculation. Groups of 4-to 6-week-old C57BL/6 mice (mixed sex) were infected intra-nasally with 10 5 pfu of wild-type VV (panel A) or VVE3LD83N (panel B). At 2, 4, and 6 days post-infection animals were sacrificed in triplicate and nasal turbinates, lung and brain tissue were harvested and titrated on RK-13 cell monolayer (see Materials and methods), as previously described (Brandt and Jacobs, 2001) . Data shown are representative of two independent experiments. but failure to disseminate to the brain, or to cause disease even when injected directly into the brain, suggested that this virus might have characteristics of an improved vaccine strain. In order to determine whether intra-nasal infections with this virus could induce a protective immune response, 4-week-old mice were first infected intra-nasally with 10-10 4 pfu of VVE3LD83N. Immunized animals were challenged intra-nasally 30 days later with 2 Â 10 7 pfu of wildtype VV (WR strain). Morbidity was assayed by monitoring loss of weight (Fig. 5) . Mock-immunized, mock-challenged animals gained weight during the course of the challenge, while mock-immunized animals challenged with wild-type VV lost 20% of their initial body weight over the 10-day course of the challenge. Immunization with VVE3LD83N protected against loss of weight caused by infection with wild-type VV, in a dose-dependent manner. Immunization with 10 pfu gave partial protection from weight loss, while full protection was afforded by immunization with 100-10,000 pfu of this virus (weight gain similar to mock challenged control). Thus, VVE3LD83N protected mice from challenge with wild-type VV at immunization doses that were at least three logs lower than its LD 50 .
Vaccination against smallpox in humans is usually performed by scarification. To determine if VVE3LD83N could protect when administered by scarification, animals were vaccinated with 10 6 pfu of either wtVV or VVE3LD83N by scarification on the tail. With either virus all vaccinated animals developed pocks, and there was no significant difference in size or intensity of inflammation between pocks induced by wtVV and VVE3LD83N. Animals were challenged intra-nasally 3 months later with 10 6 pfu of wtVV (WR strain). Mock-vaccinated animals lost 20% of their body weight during the first 8 days of the challenge (Fig. 6, open boxes) . Animals vaccinated by scarification with either wtVV (Fig. 6, open triangles) or Fig. 4 . Intra-cranial infection of mice: h-galactosidase staining of infected cells. Four-week-old C57BL/6 mice were infected with 10 4 pfu of either wtVV-lacZ (panel A), or VVE3LD83N-lacZ (panel B) in the left hemisphere of the brain. At 6 days post-infection, brains were fixed by perfusion as described in Materials and methods, removed from the skull, cut into 2 mm blocks, and stained for h-galactosidase activity, using X-gal. The view shown is an anterior view of a coronal section. Fig. 3 . Intra-cranial infection of mice: dose-response and viral replication. Panel A: Groups of at least six anesthetized 4-to 6-week-old C57BL/6 mice (mixed sex) were inoculated intra-cranially in the left hemisphere with 10 Al of virus containing the indicated dose of virus. Animals were monitored daily for weight loss and mortality. Panel A shows mortality curves for intra-cranially infected mice. Panel B: To assay for virus replication in brain tissue, mice were inoculated intra-cranially with 10 Al of virus containing 10 6 pfu. Mice were sacrificed in duplicate 5 days post-infection and brain homoginates were assayed for infectious virus on RK-13 cell monolayers, as described (Brandt and Jacobs, 2001 ). VVE3LD83N (Fig. 6 , closed circles) were completely protected from challenge with wtVV.
The WR strain of VV used in these experiments is a neurovirulent, mouse adapted strain. To determine if an N-terminal mutation in E3L would affect pathogenicity and efficacy of a human vaccine strain we performed similar experiments with the Copenhagen strain of VV and Copenhagen-VVE3LD83N. WT-Copenhagen-VV was not pathogenic when administered intra-cranially into immune competent mice (data not shown) but was pathogenic when administered intra-cranially in SCID mice (Fig. 7 , open diamonds). One of five mice infected intra-cranially with 10 5 pfu of wt-Copenhagen-VV died on day 4, and the remaining mice lost weight throughout the course of the experiment (25% weight loss by day 15). Mice infected with the same dose of Copenhagen-VVE3LD83N (Fig. 7 , open triangles) lost a small amount of weight on day 2 but fully recovered and gained weight in a manner indistinguishable from historic controls (data not shown). Thus, deletion of the N-terminus of E3L further attenuated the already attenuated Copenhagen vaccine strain. Mice vaccinated with Copenhagen-VVE3LD83N by scarification were fully protected from challenge with wt-WR-VV (Fig. 8) .
Discussion
In this manuscript we demonstrate that while the N-terminal domain of the E3L gene product is not necessary for efficient replication in the nasal mucosa, it is necessary Fig. 6 . Scarification vaccination of mice against wild-type vaccinia virus infection (WR strain) using VVE3LD83N. Groups of five anesthetized BALB/c mice were vaccinated by scarification with 10 6 pfu of wtVV, VVE3LD83N. Five anaesthetized mice were mock vaccinated with buffer (1 mM Tris pH 8.8). Mice were challenged intra-nasally with 10 6 pfu of wild-type VV, or mock challenged 90 days following initial infection. Data show mean change in body weight after challenge. . Intra-nasal vaccination of mice against wild-type vaccinia virus infection (WR strain) using VVE3LD83N. Groups of five anesthetized C57BL/6 mice were vaccinated intra-nasally with 10, 100, 1000, or 10,000 pfu of VVE3LD83N or buffer (mock vaccination). Mice were challenged intra-nasally with 2 Â 10 for spread of virus to the lungs and brain and is necessary for efficient replication in the brain. Recombinant virus containing an E3L gene deleted of the N-terminal domain is fully replication competent in most cells in culture . The virus also replicated to wild-type levels in nasal tissues but failed to spread from the nasal cavity either to the lungs or the brain. Despite replicating in the nasal mucosa, intra-cranial injection into the brain showed that this virus replicated poorly, if at all, in neuronal tissue. Thus this virus demonstrates a tissue specific host-range phenotype.
While the N-terminus of E3L is not necessary for replication in cells in culture, several biochemical characteristics have been mapped to this domain. The E3L gene products are found both in the nucleus and cytoplasm of infected cells (Yuwen et al., 1993) . We have shown that the N-terminus is required for nuclear localization of the E3L gene products: E3LD83N is excluded from the nucleus of infected cells (Chang et al., 1995) . The role of nuclear localization in pathogenesis in mice is at present unclear. The N-terminus of E3L has homology to the Z-DNAbinding domain (Za) of the RNA-editing enzyme, ADAR-1 (Kim et al., 2003) . The E3L gene products bind to Z-DNA, although with lower affinity than ADAR-1 (Kahmann et al., 2004) . We have recently shown that the ADAR-1 Za domain can complement the N-terminus of E3L for neurovirulence, and that neurovirulence correlates with binding to Z-DNA among mutants of E3L and an ADAR-1 Za/E3L dsRNA-binding domain chimera (Kim et al., 2003) . While the ADAR-1 Za can complement loss of the N-terminus of E3L for intra-cranial infection (neurovirulence), the ADAR-1 Za complements poorly on intra-nasal infection (Muralinath, Hauns and Jacobs, unpublished observations), suggesting that the N-terminus has two separable functions for spread from the nasal cavity and neurovirulence.
The E3L gene products can inhibit activity of ADAR-1 and the N-terminus of E3L has been implicated in this inhibition of enzyme activity (Liu et al., 2001 ). Since ADAR-1 is highly expressed in brain (Paul and Bass, 1998) , it is possible that the failure to inhibit ADAR-1 in the brain may be responsible for the decrease in neurovirulence of viruses containing N-terminal mutations in E3L.
The E3L gene products are potent inhibitors of the antiviral enzymes PKR and OAS (Jacobs and Langland, 1996) , and the N-terminal domain is necessary for inhibition of these enzymes at very late times post-infection in cells in culture (Langland and Jacobs, 2004) . While failure to inhibit PKR and OAS at very late times post-infection does not lead to any phenotypic difference in cells in culture, it is possible that it is responsible for some of the phenotypes seen in infected animals. Consistent with this, VVE3LD83N led to high levels of eIF2a phosphorylation (eIF2a is the main substrate for active PKR in infected cells) in the nose, but not the brain of infected animals (Langland and Jacobs, 2004) .
Vaccinia virus is the vaccine for protection against smallpox and is being developed as a vector for immunization against heterologous pathogens and cancer. The current vaccine strains for protection against smallpox cause a relatively high rate of complications, including encephalitis in young children (Fenner et al., 1988) . Development of a safer vaccine that can protect against smallpox is a high priority. Since VVE3LD83N replicated to wild-type titers at the site of infection, but failed to spread, and was reduced over 1000-fold in terms of neurovirulence, we investigated its ability to immunize against challenge with pathogenic wild-type VV. Immunization of 4-week-old mice intranasally with 100-10,000 pfu of VVE3LD83N fully protected against challenge 4 weeks later with a large dose of wild-type VV. Thus a protective dose is from 3 to 5 logs lower than a pathogenic dose with this virus. Vaccination with this virus by scarification also protected against an intra-nasal challenge with wtVV. These results demonstrate that this replication competent, attenuated mutant of VV can indeed induce a protective immune response in mice. It is likely that any vaccine based on a similar mutation in the E3L gene would cause fewer complications in humans than a wild-type VV-based vaccine. In fact, Copenhagen-VVE3LD83N is attenuated compared to the parental vaccine strain but still induces a protective immune response in vaccinated mice.
Vaccinia viruses containing attenuating mutations in other non-essential genes have been studied as potential vaccines (Buller et al., 1985; Lee et al., 1992; Legrand et al., 2004; Verardi et al., 2001 ). Mutation of the TK gene of VV decreases neurovirulence to approximately the same level as the E3LD83N mutation, while having no effect on replication in cells in culture (Buller et al., 1985; Lee et al., 1992) . Mutation of serpin genes or the IFNg receptor homologue also attenuates, without affecting immunogenicity developed toward a heterologous antigen (Legrand et al., 2004; Verardi et al., 2001) . However, it is not possible to compare the level of attenuation of these viruses relative to VVE3LD83N. Protection against challenge with a pathogenic poxvirus has not been reported for these other attenuated strains of VV.
Materials and methods
Virus construction
Viruses were constructed by targeted in vivo recombination (IVR) of WRDE3L with pMPDE3L plasmid encoding the respective mutant E3L gene (D37N, D54N, or D83N) cloned between homologous recombination flanking arms as previously described (Brandt and Jacobs, 2001; Kibler et al., 1997) . Wild-type E3L reconstruction revertants were then made by recombination of the wild-type E3L gene into mutant viral constructs. Insertion of the Escherichia coli lacZ gene into the intergenic region between E2L and E3L will be described elsewhere.
Cell culture
RK13 cells were cultured in MEM (Gibco, BRL) containing 5% FBS, 50 Ag/ml gentamycin, and 0.1 mM non-essential amino acid solution (MEM5%) (Gibco, BRL). Cells were incubated at 37 8C with 5% CO 2 . BHK-21 cells were cultured in MEM (Gibco, BRL) containing 10% FBS and 50 Ag/ml gentamycin (MEM10%) and incubated at 37 8C with 5% CO 2 . HeLa S3 cells were cultured in DMEM (Gibco, BRL) with 5% FBS (DMEM5%) and incubated at 37 8C with 5% CO 2 .
In vivo infections
C57BL/6 and BALB/c breeders were obtained from Charles River, and colonies were maintained pathogen-free by the Animal Resource Center at Arizona State University. SCID mice (CB17) were obtained directly from Charles River. Four-to five-week-old mice were randomized such that each cage contained at least 6 mice with approximately equal average body weight and equal numbers of each sex. A separate cage was used for each experimental condition (dose of each virus). An anesthetic cocktail was prepared containing 7.5 mg/ml xylazine (Phoenix Pharmaceuticals, St. Joseph, Missouri), 2.5 mg/ml acepromazine maleate, and 37.5 mg/ml ketamine (Fort Dodge Laboratories, Fort Dodge, Iowa). Approximately 1 Al of cocktail was injected per gram of mouse weight via the intra-muscular route.
Following anesthesia, virus was administered intra-nasally (using pipetman with a gel loading tip) in doses containing 10 3 -10 8 pfu VV in 5 Al 1mM Tris, pH 8.8. Mice were observed daily for body weight loss and morbidity (Reed and Muench, 1938) .
Intra-cranial inoculations were performed following anesthesia as above. Ten microliters of virus containing various titers of virus in 1 mM Tris pH 8.8 was injected intra-cranially using a 26-gauge hypodermic needle and 1 cc syringe (B-D). Weight loss was determined by weighing individual mice every day or on alternate days postinfection. The percent weight gain or loss over time was determined simply by averaging the weights per cage at each time point divided by the initial average weight.
For infection by scarification, fur was removed from the skin at the base of the tail of BALB/c mice using Nair hair remover and 15 scratches were made horizontally across the tail using a 26-gauge needle. Ten microliters of virus in 1 mM Tris, pH 8.8, was pipetted onto the abraded skin and rubbed in with the side of the pipette tip.
Tissue distribution C57BL/6 mice between 4 and 5 weeks old were randomized so that each cage contained equivalent number of males and females. The mice were anesthetized and infected intra-nasally or intra-cranially, as described above. Three mice inoculated with each virus recombinant and three uninfected controls were sacrificed on days 2, 4, and 6 post-infection and the brain, lungs, and nasal turbinates were harvested and frozen in liquid nitrogen. Each tissue was homogenized (nasal turbinates required additional grinding with sand) on ice and made into 10% tissue suspensions using MEM containing 5% FBS and 100 Ag/ml of gentamycin. Tissue suspensions underwent three rounds of freezing (À80 8C) and thawing (37 8C) and cell debris was removed by centrifugation (4 8C). Virus titers were determined for tissue samples by titration using RK-13 cell monolayers.
For the histochemical identification of VV replication in brains, 4-to 5-week-old C57bl/6 (Charles Rivers Laboratory) were anesthetized prior to intra-cranial injection of 10 4 pfu of wtWR-lacZ or WR-E3LD83N-lacZ (lacZ inserted into the intergenic region between E3L and E3L; construction of these viruses will be described elsewhere) into the left hemisphere. Brains were removed 4 days post-infection after cardiac perfusion with 4% paraformaldehyde in PBS (pH 7.4). The tissues were saturated with 30% sucrose, sliced using a 2-mm tissue block, and stained with X-gal solution as previously described (Bloom and Jarman, 1998) .
